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Abstract
Purpose We aimed to investigate the effects of FSH for pro-
moting spermatogenesis in mice with low-dose doxorubicin-
induced spermatogenesis impairment.
Methods Eight-wk-old male imprinting control region mice
were divided into three groups. Groups D and F received
0.5 mg/kg of doxorubicin twice weekly for 5 weeks. Group
C received saline instead of doxorubicin. After inducing sper-
matogenesis impairment, group D was treated daily with sa-
line for 4 weeks. Group F was given 1 IU of recombinant
human FSH daily for 4 weeks. Spermatogenesis recovery
was evaluated based on the testis weight, sperm count, histo-
logical assessment, and mating. The percentage of sperm with
unfragmented deoxyribonucleic acid (DNA) was analyzed by
single-cell pulsed-field gel electrophoresis, and the serum
FSH levels were measured.
Results The elevation of serum FSH advanced slowly. The
testis weight, sperm count, percentage of seminiferous tubules
with spermatogenesis , percentage of sperm with
unfragmented DNA and pregnancy rate were significantly
increased by the administration of FSH.
Conclusion Our study findings indicated that the immediate
administration of exogenous FSH can promote the recovery
from impaired spermatogenesis induced by low-dose doxoru-
bicin before endogenous FSH increases to the maximum
level.
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Introduction
The increasing success rate of cancer treatment has improved
long-term survival and patients’ quality of life. However,
gonadotoxicity is a frequent adverse effect of cancer treat-
ment. The two most common diagnoses in younger age
groups are testicular tumor and hematopoietic malignancy.
In previous testicular tumor cases, 56 and 20 % of patients
did not recover normal sperm count after 1 and 3–5 years,
respectively [1]. In lymphoma, cyclophosphamide,
hydroxydaunorubicin, oncovin, and prednisone chemothera-
py using cyclophosphamide, doxorubicin, vincristine and
prednisone caused azoospermia in almost 100 % of patients,
one-third of whom still had the disorder after 5 years [2]. The
only method for extracting sperm from azoospermia patients
is microdissection testicular sperm extraction. However, in a
report by Hsiao et al., the sperm retrieval rate was 37%, which
decreased when the patients received alkylating agents [3].
Henceforth, sperm cryopreservation has been considered the
standard pretreatment procedure. However, this option is not
available in emergency or prepubertal cases. In fact, 60 % of
hematopoietic malignant patients who were referred to our
institution underwent remission reduction therapy without a
prior cryopreservation procedure (data not published), and
most of them had worsening semen analysis results.
Capsule The administration of exogenous FSH promotes the recovery
from impaired spermatogenesis induced by low-dose doxorubicin.
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Moreover, although the exact cause has not been well
established, oligozoospermia occurs more frequently in pa-
tients with cancer than in healthy men [3, 4]. In our experi-
ence, semen cryopreservation is not feasible in patients with
poor semen quality even in those who have not yet undergone
chemotherapy.
Several trials have reported on the use of hormonal
treatment for enhancing the recovery from radiation- or
chemical-induced spermatogenesis impairment in animal
models. For example, gonadotropin-releasing hormone
(GnRH) and exogenous testosterone are commonly used
[5–7]; however, these hormones are associated with side
effects such as a decreased libido and risk of impaired
spermatogenesis caused by negative feedback. In healthy
animals, the follicle-stimulating hormone (FSH) and tes-
tosterone regulate and play valuable roles in spermatogen-
esis. In rodents, FSH influences the development of sper-
matogonia by controlling their survival mechanisms [8].
The activities of FSH and testosterone are important for
meiosis progression and spermiation [9]. However, the
use of FSH and luteinizing hormone (LH) under a high
plasma gonadotropin level is ineffective, because the re-
ceptors in the Sertoli and Leydig cells lose their sensitivi-
ties [10]. To the best of our knowledge, there are no studies
on the effect of FSH therapy on chemically induced sper-
matogenesis disorders.
Furthermore, in most models, testicular damage is
induced by the single administration of a high-dose
chemoagent, and the hormones are administered preven-
tively. Doxorubicin (DXR) is an anthracycline antibiotic
anticancer agent that is widely used in the treatment of
several malignant diseases such as hematopoietic malig-
nancy. The mechanism of action of DXR is the suppres-
sion of deoxyribonucleic acid (DNA) synthesis by
inhibiting polymerase activity and consequently interfer-
ing with cell proliferation. Additionally, other mecha-
nisms such as increasing oxidative stress and inducing
cellular apoptosis are known to cause testicular damage
[11].
We aimed to investigate whether FSH therapy stimulates
the regeneration of spermatogenesis in mice after exposing
them to low-dose continuous regimen of DXR in order to
induce chronic and reversible spermatogenesis dysfunction.
In addition, we analyzed male fertility by assessing sperm
quality via DNA fragmentation and mating experiments.
Materials and methods
Reagents
We used DXR (Sandoz Co., Tokyo, Japan), recombinant hu-
man FSH (MSD Co., Tokyo, Japan).
The DXR treatment duration and dose were based on a
previous report [12], and the findings from our preliminary
study showed that DXR causes severe but not irreversible
damage to spermatogenesis.
The recombinant human FSH (rhFSH) dose was deter-
mined from a previous dose response study in hypogonadal
mice [13]. Although their animal model was different from
that used in our experiment, they demonstrated that at least
1 IU daily of a FSH injection can stimulate spermatogenesis.
Thus, we chose 1 IU daily as our administration dose.
Animals
Eight-wk-old male imprinting control region (ICR) mice
weighing 33–35 g were purchased from Sankyo Laboratory
(Tokyo, Japan), and they were housed in wire-mesh cages (5
animals per cage) under controlled lighting conditions (12-h
light/dark cycle) at a temperature of 20–24 °C. Food and water
were provided ad libitum. All the animal housing and surgical
procedures were performed in accordance with the guidelines
of the institutional animal care and use committee of the An-
imal Research and Care Committee of the Tokyo Dental
College.
Treatment protocol
The animals were divided into three groups (Fig. 1). All the
mice, except the controls, were treated intraperitoneally with
0.5 mg/kg of DXR twice weekly (Mondays and Thursdays)
for 5 weeks. The control mice received 0.5 mL/kg of saline.
Group Cwas the control group with 32 mice that were only
treated with saline. Group C was subdivided into four groups
(eight mice each). Group C1 received 0.5 mL/kg of saline
twice weekly for 5 weeks and was sacrificed to assay hor-
mones. Groups C2, C3, and C4 were treated with saline daily
for 4 weeks after the 5 weeks of saline injections. Groups C2
and C3 were sacrificed in the 9th and 13th wk, respectively, to
Fig. 1 Experimental design and group composition. DXR, doxorubicin;
F, follicle-stimulating hormone
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assay hormones. Group C4 was sacrificed in the 21st wk to
assess spermatogenesis.
Group D (32 mice) was subdivided into four groups (eight
mice each) and received the same regimen of DXR treatment
for 5 weeks. Group D1 was sacrificed in the 5th wk to assay
hormones. Groups D2 and D3 received saline injections daily
for 4 weeks after DXR treatment, and they were sacrificed in
the 9th and 13th wk to assay hormones. Group D4 received
the same regimen of groups D2 and D3 but was sacrificed in
the 21st wk to evaluate spermatogenesis.
Group F (24 mice) was subdivided into three groups (eight
mice each) and was treated with the same regimen of DXR for
5 weeks followed by 1 IU of rhFSH daily for 4 weeks. Groups
F1 and F2 were sacrificed in the 9th and 13th wk, respectively,
to evaluate the hormones, and group F3 was sacrificed in the
21st wk after the mating experiments.
Histological analysis was performed at 21st wk to have
enough intervals after DXR treatment (>35 days is the sper-
matogenesis cycle of mice) [14]. Additionally, we evaluated
the recovery of spermatogenesis at this point, according to a
previous report that use the same DXR treatment protocol in
which the difference in the pregnancy rate was observed [12].
In the mating experiments, each male of groups C4, D4,
and F3 was cohabited with two 8-weeks-old ICR virgin fe-
male mice for 5 days, starting from 20 week after the initiation
of the experiment. The cohabited female mice were sacrificed
2 weeks later and were observed for possible pregnancy, and
the implantation rate. The pregnancy rate was calculated as the
number of pregnant females per the total number of females in
each group (16 females), and the percentage of implantation
was calculated as the number of implantations per the number
of corpora luteum.
Testis weight and sperm count
The weight of the left testes at 21st wk was measured without
peeling the tunica. To determine the sperm counts, sperm
samples from the cauda epididymides were collected, as pre-
viously reported [15]. Briefly, the epididymides were removed
and were placed in 3 mL of normal saline, and then they were
minced to allow the sperm to swim for 10 min at 37 °C. The
sample were diluted with trypan blue staining solution, and
they were transferred into a hemocytometer to determine the
cauda sperm count.
Histological evaluation of spermatogenesis
The right testes were fixed in Bouin’s solution and were em-
bedded in paraffin. Each section was stained with hematoxylin
and eosin and was examined under a light microscope. To
determine the proportion of tubules showing spermatogenesis,
we counted the number of seminiferous tubules per section
with or without spermatogenesis, as previously reported [16].
Briefly, each tubule was considered positive when at least two
layers of germ cells on the whole circumference of the basal
membrane were present. This phenomenon represents the re-
generation of spermatogenesis, which was promoted by the
hormone therapy aimed at repairing the damage resulting from
the DXR treatment. For quantitative evaluation, at least three
sections with 100 tubules per section were examined in each
testis.
Hormone assays
To examine the serum FSH and testosterone levels, 1 mL of
blood was obtained from the jugular veins of each mouse
before euthanasia. Then the blood sample was centrifuged to
isolate the plasma, and it was stored at -80 °C until analysis
[17]. The FSH and testosterone levels were measured using
the Rodent FSH ELISA TEST Kit (Endocrine Technologies
Co., Newark, CA, USA) and Rodent Testosterone ELISA
TESE kit (Endocrine Technologies Co.).
Single-cell pulsed-field gel electrophoresis
To assess the characterization of sperm quantitatively, single-
cell pulsed-field gel electrophoresis (SCPFGE) was per-
formed to observe fragmented DNA derived from single
sperm nucleus [18]. Briefly, an aliquot of sperm (2×104 cells)
was applied to amino propyl-silane-conjugated glass slides,
which were embedded in melted 0.56 % agarose mixed with
purified trypsin, and they were chilled for 30 min. The gel was
incubated in the cell-lysis reagent (30 mM Tris-
polyphosphoric acid, 8.2 mM sodium hexa-metaphosphate,
0.05 % Triton X-100, 5.0 mM dithiothreitol, at pH 8.1) at
37 °C for 30 min. SCPFGE was performed at 1.5 V/cm with
3.0 s intervals for 7 min. DNA in the gel was stained with
diluted (×104) Cyber-Gold (Molecular Probes, Eugene, OR,
USA) and was observed under an epifluorescent microscope.
We classified the profiles of DNA according to the sizes of
fragmented DNA as long chain fiber elongated from the origin
without interruption (Fig. 2a), and the others with granular or
fibrous fragments were separated beyond the anterior end of
the elongated long chain fiber (Fig. 2b). When DNA fragmen-
tation is advanced, long chain fibers will decrease and short-
ened, while the granular or fibrous fragments will increase. In
each specimen, > 100 sperm were observed and the percent-
age of sperm that had long chain fiber without containing
granular or fibrous fragments was counted.
Statistical analysis
Statistical analyses were performed to analyze differences be-
tween the groups. Analysis of variance was used to examine
the differences between all the groups, followed by a nonpara-
metric Mann–WhitneyU -test to determine the significance of
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the differences between the pairs of groups. Values were
expressed as mean±standard error of the mean. Results were
considered significant at p<0.05. The analyses were per-
formed using JMP statistical software program, version 5.0
(SAS Institute Inc., Cary, NC, USA).
Results
Body and testis weight and sperm count
All the animals were alive during the DXR treatment and
showed increasing body weight. Although body weight de-
creased in some groups after hormone administration, no sta-
tistically significant differences were observed between the
groups.
In week 21, the testis weight increased in group F com-
pared to that in group D. In accordance with changes in the
testis weight, the epididymis cauda sperm count was statisti-
cally increased in group F compared to that in group D
(Table 1).
Histological analysis of spermatogenesis
On histological examination, most of the tubules were com-
posed of mature spermatid and sperm cells.in the control
group’s testes (group C) (Fig. 3a and b). In the DXR treated
testes (group D), the diameters of the testicular tubules were
reduced, and the seminiferous tubules showed vacuolization
and a reduced germ cell count. As the impairment progressed,
the testicular tissues became atrophic and the germ cells in the
tubules disappeared, with only Sertoli cells remaining (Fig. 3c
and d). The ratio of atrophic tubules was decreased and the
number of tubules composed of mature spermatid and sperm
cells were increased in the FSH-treated groups’ testes (group
F) (Fig. 3e and f).
A quantitative assessment of the recovery from the DXR-
induced disorder showed that the proportion was increased in
group F compared to that of group D (Table 1).
Sperm quality and fertility
The percentage of sperm that did not containing granular or
fibrous fragments was increased in group F (Table 1). Similar
to the sperm quality study, the animals in group F showed a
significant and drastic recovery in the pregnancy rate
(Table 1). Implantation rate decreased significantly in group
D compared with control group C. It recovered in group F;
however there was no statistical difference between in group
D (Table 1).
Hormone assays
The serum FSH level increased gradually in response to DXR
treatment, and the increase became significant at 13 and
21 week compared to the control group (C) (P<0.05). The
serum FSH level increased in response to treatment with
rhFSH in week 9, although the difference did not reach statis-
tical significance compared to the control group (C). In week
Fig. 2 Single-cell pulsed-field gel electrophoresis is performed to
observe the fragmented deoxyribonucleic acid (DNA) derived from the
single sperm nucleus. (a) The long chain fiber is elongated from the origin
without interruption in sperm without impairment of DNA. (b) Granular
or fibrous fragments are separated beyond the anterior end of the
elongated long chain fiber when the DNA fragmentation is advanced
Table 1 Parameters related to the
recovery of spermatogenesis Group C D F
Testes weight (mg) 133±2.73 * 62±4.98 108±6.25 *
Sperm concentration (×106/mL) 6.6±1.6 * 3.4±0.79 6.1±1.7 *
% of tubulues with spermatogenesis 84±5.5 * 33±6.4 56±7.8 *
Mating experiment
% of pregnant female 93.7 * 25 75 *
% of implantations 82.2±15.8 * 25.3±38.8 48.1±27.9
% of sperm with long chain fragment 84.1±1.7 * 29.7±5.2 84.0±4.8 *
Mean±SE
*P<0.05 vs group D
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13 and 21, the FSH level was decreased significantly in group
F compared to that in group D (P<0.05) (Fig. 4a).
The serum testosterone levels tended to decrease in the
DXR-treated groups (D and F) compared to the control (group
C); however, the significant difference was only observed at
21 week for group D (Fig. 4b).
Discussion
Treatment methods for hematopoietic malignant disease and
testicular cancer have improved in recent years. Sperm cryo-
preservation provides young patients with the opportunity to
pursue marriage and procreation, which are considered impor-
tant factors that affect quality of life. However, the option to
undergo sperm cryopreservation is not available for patients
who have been previously treated with chemoagents such as
those undergoing remission induction therapy against acute
leukemia, and most of these patients have reduced semen
parameters. Our present study demonstrated the efficacy of
FSH treatment for promoting spermatogenesis after DXR-
induced damage in mice. Furthermore, we confirmed sperm
quality by using SCPFGE, which has not been performed
previously in the same kind of studies.
When spermatogenesis is disturbed by radiation or chemo-
therapy, endogenous gonadotropins may be produced at high
levels. Generally, it is ineffective to administer FSH or LH in
the presence of a high plasma gonadotropin level because of
the desensitization of the FSH and LH receptors in Sertoli and
Leydig cells. Moreover, Meistrich and Shetty described the
inhibition of spermatogenesis by testosterone or FSH under
pathological conditions [19]. Therefore, the aim of hormone
treatment was thought to decrease the FSH level, reset testic-
ular activity and restore the function of the Sertoli and Leydig
cells [5, 20]. In the present study, early FSH administration
was effective for the recovery of spermatogenesis and fertility.
Our findings contradict those of a study that show that the
administration of exogenous FSH under conditions of
hypergonadotropin did not improve Sertoli cell function [20].
This discrepancy can be attributed to the differences be-
tween the methods of testicular impairment used. DXR, an
anticancer agent used in several malignant diseases, causes a
dose-dependent spermatogenesis disturbance in experimental
animals [12, 21–24]. Lu et al. and Meistrich et al. demonstrat-
ed that single-dose DXR induced the spermatogenesis disor-
der [21, 23], whereas at low doses, it caused a mild and chron-
ic spermatogenesis disorder in mouse models [12]. In the
present study, the administration of low-dose DXR (0.5 mg/kg
twice per week) for a long period (5 weeks) caused a chronic
disorder that was different from those previously reported in
animal models, in which impairment was induced by a single
high-dose injection of chemoagents or radiation. In fact, the
serum FSH level did not increase early; it increased gradually
in the later weeks of this model (Fig. 4a), which is different
from the findings of previous studies in which the FSH was
elevated after 6 weeks of procarbazine treatment [25]. There-
fore, we assume that if the serum FSH elevated to a peak level
at once, the FSH becomes harmful and the Sertoli cells lose
their sensitivity. Meanwhile, the FSH sensitization in Sertoli
cells would remain before the serum FSH levels increase with
the passage of time after DXR treatment, and this may be
stimulated by exogenous FSH.
DXR induces testicular impairment through several mech-
anisms. Reactive oxygen stress causes serious damage and
some antioxidant enzymes attenuate the disorder. Xin et al.
reported on the increase in the percentage of abnormal sper-
matozoa in DXR-treated rats [26]. In fact, we showed that
DNA fragmentation was severe in the DXR-treated group
(D) (Table 1). In group D, the number of pregnant females
was low even though the sperm existed. We expected that the
reduction in the sperm count and quality may have caused the
decrease in pregnant females of the mating study.
Fig. 3 Histopathological findings in the testes that were sacrificed in the
21st week (hematoxylin and eosin staining). (a and b) Most of the tubules
are composed of mature spermatid and sperm cells in the control testes
shown in (a) under a higher magnification in (b) (paraffin section of
group C). (c and d) The doxorubicin-treated testes show shrunken
tubules. The thickness of the seminiferous tubules is reduced, and the
germ cell layer is decreased. In some seminiferous tubules,
vacuolization and a reduced number of germ cells observed. The
impairment has progressed, and the testicular tissue has become fibrous
and atrophic (paraffin section of group D). (e and f) In the follicle-
stimulating hormone-treated testes, the percentage of atrophic tubules is
decreased and the number of tubules that compose the of mature
spermatids and sperm cells is increased (paraffin section of group F).
Scale bar=100 μm
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DXR may cause the impairment of spermatogonial cells.
The spermatogonia are classified as spermatogonial stem
cells, proliferative and differentiating spermatogonia. Lu and
Meistrich reported that differentiated spermatogonia (A2)
were most sensitive; however, stem cells were also killed with
doses of DXR [21]. Although the experimental model is dif-
ferent from previous reports, the recovery of spermatogenesis
observed in our study suggests that spermatogonial stem cells
may remain under the exposure of DXR, and they react to
FSH stimulation. However, there were several tubules existing
only in the Sertoli cells without germ cells (Fig. 3). Moreover,
the sperm count and quality did not increase in group D even
though there were enough recovery periods. This suggests that
the spermatogonial stem cells were also one of the targets of
DXR. In our study, we suppose that DXR widely induced the
germ cell disorder among spermatogonial stem cells to differ-
entiated spermatogonia.
Meistrich and Shetty reported that testosterone inhibited
spermatogenesis under pathological conditions [19]. Howev-
er, in past reports on inducing testicular damage by
chemoagents or radiation, the level of testosterone did not
seem to be directly related to spermatogenesis recovery. The
change in testosterone levels after the impairment differed
among each report. Meistrich and Kangasniemi reported that
the serum testosterone level showed no change by irradiation
[5]. Meanwhile, procarbazine reduced the testosterone level
after 6 weeks [25]. In fact, in our study, the testosterone level
decreased by 21 week after DXR treatment (group D) com-
pared to the control (group C); however there was no signif-
icant difference between the FSH-treated group (F) (Fig. 4b).
FSH acts at various stages starting from the regulation of
the spermatogonial population through spermiogenesis in ro-
dents [9, 27–30]. In our study, the sperm concentration and
percentage of seminiferous tubules with spermatogenesis was
elevated in the FSH-treated group (group F). Furthermore, the
testis weight, pregnancy rate in the mating study, and recovery
of DNA fragmentation of sperm were higher in group F than
in the control (group C). Assuming that the testes retained
sensitivity to the FSH, efficacy of the FSH in our study sug-
gests that early FSH administration increased spermatogonia
and promoted spermatogenesis regeneration. The FSH will
not directly act with spermatozoa (i.e., sperm differentiated
from the remaining spermatogonia may have had some im-
pairment). However, unimpaired sperm newly differentiated
from spermatogonia that were increased by FSH stimulation
recovered in their quality.
There are some differences in spermatogenesis between
primates and rodents, especially in stem cell populations
[31]. Additionally, Lu and Meistrich reported that the effect
of DXR on testicular stem cells in humans were less signifi-
cant than that on mice [21]. Although the sensitivity of che-
motherapy is not similar, we hope that our study may become
one of the clues for recovering the fertility of young patients
who have received chemotherapy.
In conclusion, we showed that early treatment with exoge-
nous FSH before the elevation of endogenous FSH promoted
recovery from the damage of spermatogenesis induced by
low-dose, long-duration DXR administration in mice.
Conflict of interest The authors declare none.
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